Xue-Han Liu

Xue-Han Liu

Auto-generated profile, based on publicly available information

Xue-Han Liu

Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2019 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
DKDe Zhao Kong
De Zhao Kong
NLNing LIANG
Ning LIANG
GYGuan Lin Yang
Guan Lin Yang
ZZZhe Zhang
Zhe Zhang
YLYue Liu
Yue Liu
JLJian Ping Liu
Jian Ping Liu

17 August 2022 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
NDNing Dai
Ning Dai
QHQingyun He
Qingyun He
XLXuehan Liu
Xuehan Liu
MFMin Fang
Min Fang
MXMin Xiong
Min Xiong
JLJianping Liu
Jianping Liu

26 September 2018 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CLChun-Li Lu
Chun-Li Lu
XLXue-Han Liu
Xue-Han Liu
TSTrine Stub
Trine Stub
AKAgnete E. Kristoffersen
Agnete E. Kristoffersen
SLShi-Bing Liang
Shi-Bing Liang
JLJian-Ping Liu
Jian-Ping Liu
Due to limitations of conventional medicine for atopic eczema (AE), complementary and alternative medicine (CAM) is widely used as an alternative, maintaining, or simultaneous treatment for AE. We aimed to evaluate the beneficial and harmful effects of CAM for children with AE under 14 years old. We searched for randomized trials on CAM in 12 Chinese and English databases from their inception to May 2018. We included children (< 14 years) diagnosed with AE, who received CAM therapy alone or combined with conventional medicine. We extracted data, and used the Cochrane “Risk of bias” tool to assess methodological quality. Effect was presented as relative risk (RR) or mean difference (MD) with 95% confidence interval (CI) using RevMan 5.3. Twenty-four randomized controlled trials involving 2233 children with AE were included. Methodological quality was of unclear or high risk of bias in general. The trials tested 5 different types of CAM therapies, including probiotics, diet, biofilm, borage oil, and swimming. Compared to placebo, probiotics showed improved effect for the SCORAD index (MD 9.01, 95% CI 7.12–10.90; n = 5). For symptoms and signs such as itching, skin lesions, CAM combined with usual care was more effective for symptom relief ≥95% (RR 1.47, 95% CI 1.30–1.68; n = 8), and for ≥50% symptoms improvement (RR 1.34, 1.25–1.45; n = 9) compared to usual care. There was no statistic significant difference between CAM and usual care on ≥95% improvement or ≥ 50% improvement of symptoms. However, swimming, diet and biofilm showed improvement of clinical symptoms compared with usual care. At follow-up of 8 weeks to 3 years, CAM alone or combined with usual care showed lower relapse rate (RR 0.38, 0.28–0.51, n = 2; RR 0.31, 0.24–0.40, n = 7; respectively) compared to usual care. Twelve out of 24 trials reported no occurrence of severe adverse events. Low evidence demonstrates that some CAM modalities may improve symptoms of childhood AE and reduce relapse rate. Safety remains unclear due to insufficient reporting. Further well-designed randomized trials are needed to confirm the potential beneficial effect and to establish safety use.

1 August 2020 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
FBFan-Long Bu
Fan-Long Bu
MHMei Han
Mei Han
CLChun-Li Lu
Chun-Li Lu
XLXue-Han Liu
Xue-Han Liu
WWWei-Guang Wang
Wei-Guang Wang
JLJian-Ping Liu
Jian-Ping Liu

1 December 2018 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
BLBao-Yong Lai
Bao-Yong Lai
NLNing LIANG
Ning LIANG
HCHui-juan Cao
Hui-juan Cao
GYGuo-Yan Yang
Guo-Yan Yang
LJLi-Yan Jia
Li-Yan Jia
JLJian-Ping Liu
Jian-Ping Liu

19 October 2021 in Integrative Medicine Research
Verified
Journal Article
Open access
CLChun-Li Lu
Chun-Li Lu
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
XXXue Xue
Xue Xue
XZXiao-Wen Zhang
Xiao-Wen Zhang
XLXue-Han Liu
Xue-Han Liu
JLJian-Ping Liu
Jian-Ping Liu
We aimed to investigate use of infection control behaviours, preventative and therapeutic interventions, and outcomes among respondents to an online survey during the COVID-19 pandemic in China. The survey was designed by an international team, translated and adapted to simplified Chinese, including 132 kinds of traditional Chinese medicine (TCM) preparation recommended by guidelines. It was distributed and collected from February to May 2021, with data analysed by WPS spreadsheet and wjx.cn. Descriptive statistics were used to describe demographics and clinical characteristics, diagnosis, treatments, preventative behaviours and interventions, and their associated outcomes. The survey was accessed 503 times with 341 (67.8%) completions covering 23 provinces and four municipalities in China. Most (282/341, 82.7%) respondents reported no symptoms during the pandemic and the majority (290/341, 85.0%) reported having a SARS-CoV-2 PCR test at some point. Forty-five (13.2%) reported having a respiratory infection, among which 19 (42.2%) took one or more categories of modern medicine, e.g. painkillers, antibiotics; 16 (35.6%) used TCM interventions(s); while seven respondents combined TCM with modern medicine. All respondents reported using at least one behavioural or medical approach to prevention, with 22.3% taking TCM and 5.3% taking modern medicines. No respondents reported having a critical condition related to COVID-19. We found evidence of widespread use of infection control behaviours, modern medicines and TCM for treatment and prevention of COVID-19 and other respiratory symptoms. Larger scale studies are warranted, including a more representative sample exploring TCM preparations recommended in clinical guidelines.